rAAV Progranulin Gene Therapy for Frontotemporal Dementia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Gaucher disease and fronto-temporal dementia with GRN mutation are inadequate, particularly for neurological manifestations, and there is a need for disease-modifying therapies that effectively address these conditions.
Innovation Solution
A method involving the administration of a recombinant adeno-associated virus (rAAV) vector encoding a progranulin protein, combined with immunosuppressants like sirolimus, methylprednisolone, rituximab, and prednisone, to treat and suppress immune responses in subjects with fronto-temporal dementia, utilizing specific nucleotide sequences and capsid proteins for targeted gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy, chaperone-like small molecule drugs, or substrate reduction therapy are used to treat Gaucher disease, then peripheral disease symptoms (hepatosplenomegaly, bone marrow insufficiency, lung disorders) are improved, but neurological manifestations (seizures, cognitive deficits, movement disorders) remain refractory to treatment
Solution Approach 1:
The treatment approach is segmented into two distinct components: (1) conventional therapies (enzyme replacement, chaperone drugs, substrate reduction) targeting peripheral manifestations, and (2) gene therapy using rAAV vectors delivering functional GBA or GRN genes specifically targeting neurological manifestations. This segmentation allows each therapy to address its specific domain effectively without interfering with the other.
Solution Approach 2:
Recombinant adeno-associated virus (rAAV) vectors serve as intermediaries to deliver functional copies of the GBA or GRN genes directly into neuronal cells of the central nervous system. The rAAV capsid proteins (such as AAV9, AAVrh10, AAVrh74) act as mediators that enable efficient crossing of the blood-brain barrier and specific transduction of neuronal tissues, thereby delivering the therapeutic genetic material to the target site.
2Reliability
If rAAV vector encoding progranulin protein is administered to treat fronto-temporal dementia with GRN mutation, then progranulin expression is increased and immune response is suppressed, but the complexity of the treatment regimen increases due to combination with multiple immunosuppressants
Solution Approach 1:
Immunosuppressive therapy is administered in advance (prior to rAAV injection) and continued for a defined period after injection to preemptively suppress the immune system's response to the viral vector and transgene product. This preliminary and sustained immunosuppression prevents immune-mediated clearance of the rAAV vector and degradation of the expressed progranulin protein, thereby ensuring stable and prolonged therapeutic expression.
Solution Approach 2:
The treatment regimen combines multiple immunosuppressive agents (such as sirolimus, methylprednisolone, rituximab, and prednisone) with the rAAV vector therapy to create a composite treatment approach. This combination targets different aspects of the immune response (T cells, B cells, macrophages, antibody production) simultaneously, providing comprehensive immunosuppression to protect the gene therapy from immune rejection.
Data Source
AI summary
The disclosure relates to compositions and methods for treatment of neurodegenerative disorders, such as fronto-temporal dementia (FTD). The disclosure provides methods of treating FTD by administering expression constructs comprising a transgene encoding progranulin or a portion thereof to a subject in need thereof.